All In Biotech

Drug Trial Radar · NCT07881835

A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments

A PHASE-4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY EVALUATING ELRANATAMAB AS MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN INDIA, WITH AT LEAST FOUR PRIOR THERAPIES, INCLUDING AN IMMUNOMODULATORY AGENT, A PROTEASOME INHIBITOR AND AN ANTI-CD38 ANTIBODY

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Oct 22, 2026

Primary completion

Feb 16, 2029

Study completion Feb 16, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India. Eligible participants must have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. All enrolled participants will receive elranatamab; there is no comparator or control arm. Approximately 100 participants are planned to be enrolled across approximately 10 study sites in India. Study assessments will include evaluation of disease response and monitoring of adverse events in accordance with the study protocol.

Conditions

  • Relapsed/Refractory Multiple Myeloma
  • Multiple Myeloma

Interventions

  • ElranatamabDrug

    Elranatamab is a bispecific T-cell-engaging monoclonal antibody targeting B-cell maturation antigen (BCMA) and CD3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: From first dose of elranatamab through the End-of-Treatment visit -approximately 12 months after enrollment)
  2. Laboratory AbnormalitiesTime frame: From first dose of elranatamab through the End-of-Treatment visit -approximately 12 months after enrollment)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.